Clinical Trial Update: CHOP Plus Mosunetuzumab as First Line in Patients With Richter´s Syndrome: a Phase II Study of the Spanish Group of CLL [Phase 2]

View source ↗

Summary

A Phase II trial in Spain is evaluating CHOP chemotherapy plus mosunetuzumab as first-line treatment for Richter syndrome. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Richter Syndrome

Drugs mentioned

• CHOP chemotherapy regimen (cyclophosphamide-doxorubicin-vincristine-prednisone)
• Mosunetuzumab (mosunetuzumab)

Snippet

Sponsor: GELLC (Grupo Español de Leucemia Linfocítica Crónica) | Conditions: Richter Syndrome | Phase 2 | Status: RECRUITING